JNJ
Johnson & Johnson · Healthcare
243.04
0.44%(-1.08)
Market Closed244.14
0.45%(+1.10)
After HoursLast Updated: — ET
52W L: $141.5052W H: $251.71
$242.80
CHG+4.08 (+1.71%)
H$247.21
L$232.01
VOL99M
JNJ (1h)
Johnson & Johnson · Healthcare
Johnson & Johnson earns a Buy rating, driven by the FDA approval of its Tecvayli and Darzalex Faspro combination for R/R multiple myeloma, delivering best-in-class efficacy. This combination therapy achieved an 83.4% 36-month progression-free survival rate, significantly outperforming the control arm and expanding JNJ's addressable market. JNJ's oncology pipeline, especially in hematology, is positioned to offset Stelara's LOE, targeting $50B in oncology sales and $125B total revenue by 2030.
Defensive healthcare stocks such as Johnson & Johnson and CVS tend to outperform in recessions. Growth healthcare stocks offer higher risk and potential reward, less tied to economic cycles.
Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in Johnson and Johnson (NYSE: JNJ) by 14.4% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,003 shares of the company's stock after purchasing an additional 10,596
Bourgeon Capital Management LLC grew its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 97.4% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,134 shares of the company's stock after purchasing an additional 5,000 shares during the quarter. Bourgeon
Econ Financial Services Corp lowered its position in shares of Johnson and Johnson (NYSE: JNJ) by 87.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,484 shares of the company's stock after selling 10,404 shares during the quarter. Econ Financial Services Corp's
BTC Capital Management Inc. reduced its position in Johnson and Johnson (NYSE: JNJ) by 5.4% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 91,064 shares of the company's stock after selling 5,220 shares during the period. Johnson and Johnson comprises approximately 1.3% of BTC Capital
HEWSON MARILLYN A
director
206.492 SH @ $0.00
2026-03-10
HEWSON MARILLYN A
director
75.256 SH @ $0.00
2025-03-04
Pinto Daniel E
director
129.058 SH @ $0.00
2026-03-10
Woods Eugene A.
director
154.869 SH @ $0.00
2026-03-10
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $115.67
2026-02-27
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $247.87
2026-02-27
Decker Robert J
officer: VP Corporate Controller
4,075 SH @ $115.67
2026-02-27
Schmid Timothy
officer: EVP, WW Chair, MedTech
1,322 SH @ $245.66
2026-02-20